ProQR Therapeutics N.V.
PRQR
$1.63
$0.095.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 8.67% | -37.74% | |||
| Total Other Revenue | -4.42% | -9.65% | |||
| Total Revenue | 8.21% | -37.07% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 8.21% | -37.07% | |||
| SG&A Expenses | 15.57% | 11.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.91% | 28.90% | |||
| Operating Income | -12.15% | -147.30% | |||
| Income Before Tax | -11.28% | -186.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.28% | -207.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.28% | -207.63% | |||
| EBIT | -12.15% | -147.30% | |||
| EBITDA | -19.06% | -183.83% | |||
| EPS Basic | 8.52% | -207.32% | |||
| Normalized Basic EPS | 8.50% | -186.55% | |||
| EPS Diluted | 9.19% | -209.58% | |||
| Normalized Diluted EPS | 8.50% | -186.55% | |||
| Average Basic Shares Outstanding | 21.72% | 0.02% | |||
| Average Diluted Shares Outstanding | 21.72% | 0.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||